Every premarket decision the FDA makes on a tobacco or nicotine product is guided by one question from Congress. Is authorizing it appropriate for protecting public health, weighed across the whole population, including people who do not use the product? That last clause is easy to skim past. It is also the whole game. The law does not ask only whether a vape helps the person vaping. It asks what the product does to everyone around that person.

Advertisement

For a long time the agency had almost no data to answer the second half of its question. It now has some, and policy makers should read it.

A survey by Ipsos, commissioned by We Are Innovation (WAI), sought the non-users the statute names. It asked more than 4,000 people across five countries, including the United States, not about their own habits but about what changed when a spouse, parent, grown child, or close friend stopped smoking. These are the bystanders. They are exactly the population the public-health standard tells you to protect, and they were finally asked what they saw.

Advertisement

What the bystanders reported

The most common change in every country is the one a regulator can least dispute: less secondhand smoke. Moreover, the benefits concentrate in the household. Among Americans living with someone who quit using these products, overall quality of life improved for 67 percent, higher than among those whose person quit without such a product and higher than among friends at a distance. Reported gains in mood, confidence, and sociability followed the same pattern across all countries. The closer the relationship, the larger the effect.

Advertisement

There is a methodological point worth flagging for anyone who reviews evidence. These findings come from third parties, not the person who quit. When a smoker self-reports improvement, you discount for wishful thinking. When the partner, child, or housemate reports it independently, the discount no longer applies. This corroborates population-level benefit from observers with no incentive to flatter the product.

The youth point, taken seriously

Advertisement

The strongest argument against these products concerns young people, and it should not be waved away. Groups such as the American Lung Association warn that flavors attract teenagers and that nicotine is not harmless. These concerns deserve answers, not eye-rolls.

But the youth question has two halves, and the survey highlights the half that usually goes missing. In every country, the largest quality-of-life gains were reported by the youngest respondents, aged 18 to 34. The irony is hard to miss. The population invoked to justify restriction is the same population that benefits most when an adult in the home quits with these tools. Protecting young people from initiation and serving young adults who live with a smoker are not the same task, and policy that conflates them will get both wrong.

Advertisement

The US is already moving in the right direction

The encouraging part is that the agency has spent the past year doing something close to what this evidence recommends. The first authorizations of nicotine pouches in January 2025, six more after that, the renewed reduced-risk status for IQOS in April 2026, and the enforcement discretion plus first flavored authorizations in May all point the same way. The agency has stopped asking the binary question ban it or allow it and started asking the better one: How safe is this specific product and compared to what?

Advertisement

That is risk-proportionate regulation, and it is the right instinct. The household data gives it an empirical floor. A product that pulls a smoker off combustion not only saves the smoker, but also it clears the air for a child, calms a household, and returns shared time to a family. Those are population effects, and they belong on the benefit side of every authorization ledger.

So the request to decision-makers is narrow. Keep the product-by-product door open rather than reverting to category-wide prohibition. Count bystander and household benefit as the evidence your statute already requires, not as a sentimental extra. Police the real harm, which is sales and marketing to minors, with the full weight of the law. And move faster, because applications that sit for years keep safer options in limbo while the deadliest product stays on the shelf, fully legal.

Around 28 million Americans still smoke. The people sharing their homes are watching, and now we have a record of what they see. The standard you work under was written to protect them. The data has arrived to help you do it.

Federico N. Fernández is a visionary leader dedicated to driving innovation and change. As the CEO of We Are Innovation, a global network of over 50 think tanks and NGOs, Federico champions innovative solutions worldwide. His expertise and passion for innovation have earned him recognition from prestigious publications such as The Economist, El País, Folha de São Paulo, and Newsweek. Federico has also delivered inspiring speeches and lectures across four continents, authored numerous scholarly articles, and co-edited several books on economics.

Image generated by ChatGPT.